Related references
Note: Only part of the references are listed.The evidence framework for precision cancer medicine
Jeffrey A. Moscow et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Opportunities and Challenges in Genomic Sequencing for Precision Cancer Care
Michael L. Cheng et al.
ANNALS OF INTERNAL MEDICINE (2018)
Functional precision cancer medicine-moving beyond pure genomics
Anthony Letai
NATURE MEDICINE (2017)
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma
Shaji Kumar et al.
BLOOD (2017)
Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis
Gregory P. Kaufman et al.
BLOOD (2017)
BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics
C. Touzeau et al.
LEUKEMIA (2016)
Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax
S. M. Matulis et al.
LEUKEMIA (2016)
Chemical parsing: Dissecting cell dependencies with a toolkit of selective BCL-2 family inhibitors
Joel D. Leverson
MOLECULAR & CELLULAR ONCOLOGY (2016)
Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy
Joan Montero et al.
CELL (2015)
Precision medicine for cancer with next-generation functional diagnostics
Adam A. Friedman et al.
NATURE REVIEWS CANCER (2015)
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
Jens G. Lohr et al.
CANCER CELL (2014)
The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
C. Touzeau et al.
LEUKEMIA (2014)
Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms
B. A. Walker et al.
LEUKEMIA (2014)
ABT-737 is highly effective against molecular subgroups of multiple myeloma
Linda Bodet et al.
BLOOD (2011)
Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy
Triona Ni Chonghaile et al.
SCIENCE (2011)
Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737
Victoria Del Gaizo Moore et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Share Paper
